SciSparc unit and Clearmind publish U.S. patent application for MDMA-PEA use
SciSparc subsidiary NeuroThera Labs and Clearmind Medicine say the USPTO published a U.S. patent application covering MDMA and N-acylethanolamines, including PEA, for methods of treating PTSD, anxiety and eating disorders.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.